(Q29038503)

schizotypal personality disorder

27 March 2017

1 reference

1 reference

11

Anissa Abi-Dargham

1 reference

27 March 2017

6

Deanna M Barch

1 reference

27 March 2017

12

Jeffrey A Lieberman

1 reference

27 March 2017

7

Philip D Harvey

1 reference

27 March 2017

13

Larry J Siever

1 reference

27 March 2017

author name string

Daniel R Rosell

1

1 reference

27 March 2017

Lauren C Zaluda

2

1 reference

27 March 2017

Margaret M McClure

3

1 reference

27 March 2017

M Mercedes Perez-Rodriguez

4

1 reference

27 March 2017

K Sloan Strike

5

1 reference

27 March 2017

Ragy R Girgis

8

1 reference

27 March 2017

Erin A Hazlett

9

1 reference

27 March 2017

Richard B Mailman

10

1 reference

27 March 2017

language of work or name

English

0 references

publication date

30 July 2014

1 reference

27 March 2017

published in

Neuropsychopharmacology

1 reference

27 March 2017

volume

40

1 reference

27 March 2017

issue

2

1 reference

27 March 2017

page(s)

446-453

1 reference

Dopamine D1 receptor ligands: where are we now and where are we going

27 March 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4443959

A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia

6 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4443959

A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia

6 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4443959

Dihydrexidine--the first full dopamine D1 receptor agonist

6 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4443959

Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs

6 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4443959

Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase

6 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4443959

Parkinson's disease and D1 dopamine receptors

6 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4443959

Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkinson's disease

6 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4443959

6 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4443959

Dihydrexidine, a novel selective high potency full dopamine D-1 receptor agonist

6 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4443959

Behavioral effects in the rat of dihydrexidine, a high-potency, full-efficacy D1 dopamine receptor agonist

6 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4443959

Dihydrexidine, a novel full efficacy D1 dopamine receptor agonist

6 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4443959

Prefrontal dopamine D1 receptors and working memory in schizotypal personality disorder: a PET study with [¹¹C]NNC112.

6 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4443959

A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4443959

Characterization of in vivo pharmacokinetic properties of the dopamine D1 receptor agonist DAR-0100A in nonhuman primates using PET with [11C] NNC112 and [11C] raclopride

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4443959

Pergolide treatment of cognitive deficits associated with schizotypal personality disorder: continued evidence of the importance of the dopamine system in the schizophrenia spectrum

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4443959

Activation of dopamine D1 receptors blocks phencyclidine-induced neurotoxicity by enhancing N-methyl-D-aspartate receptor-mediated synaptic strength

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4443959

Pharmacological cognitive enhancement in schizophrenia

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4443959

Context processing in schizotypal personality disorder: evidence of specificity of impairment to the schizophrenia spectrum

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4443959

Cognitive deficits in patients with schizophrenia: effects and treatment

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4443959

GPCR functional selectivity has therapeutic impact

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4443959

Cognitive Impairment and Functional Outcome in Schizophrenia and Bipolar Disorder

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4443959

Probing cortical dopamine function in schizophrenia: what can D1 receptors tell us?

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4443959

Differential ability of D1 and D2 dopamine receptor agonists to induce and modulate expression and reinstatement of cocaine place preference in rats

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4443959

Functional selectivity of D2 receptor ligands in a Chinese hamster ovary hD2L cell line: evidence for induction of ligand-specific receptor states

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4443959

Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4443959

A 68930 and dihydrexidine inhibit locomotor activity and d-amphetamine-induced hyperactivity in rats: a role of inhibitory dopamine D(1/5) receptors in the prefrontal cortex?

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4443959

Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data

3 June 2018

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4443959

3 June 2018

https://api.crossref.org/works/10.1038%2FNPP.2014.192

Spare receptors and intrinsic activity: studies with D1 dopamine receptor agonists.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4443959

Dopaminergic benzo[a]phenanthridines: resolution and pharmacological evaluation of the enantiomers of dihydrexidine, the full efficacy D1 dopamine receptor agonist

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4443959

Working memory dysfunction in schizophrenia

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4443959

trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4443959

Dopamine receptors: pharmacological and anatomical evidences indicate that two distinct dopamine receptor populations are present in rat striatum.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4443959

The central effects of a novel dopamine agonist

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4443959

Multiple receptors for dopamine

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4443959

Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys.

3 June 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2014.192

Randomized crossover study of the histamine H3 inverse agonist MK-0249 for the treatment of cognitive impairment in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2014.192

Effects of amphetamine on visuospatial working memory performance in schizophrenia spectrum personality disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2014.192

Neuropsychological performance in schizotypal personality disorder: evidence regarding diagnostic specificity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2014.192

Neuropsychological performance in schizotypal personality disorder: importance of working memory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2014.192

D-amphetamine challenge effects on Wisconsin Card Sort Test. Performance in schizotypal personality disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2014.192

D1 agonist dihydrexidine releases acetylcholine and improves cognitive performance in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2014.192

Assessment of the effects of AZD3480 on cognitive function in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2014.192

Prefrontal dopamine D1 receptors and working memory in schizophrenia.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4443959

Conformational analysis of D1 dopamine receptor agonists: pharmacophore assessment and receptor mapping

26 November 2018

1 reference

12 December 2020

Dopamine D1 receptors: efficacy of full (dihydrexidine) vs. partial (SKF38393) agonists in primates vs. rodents

1 reference

12 December 2020

Effects of dihydrexidine, a full dopamine D-1 receptor agonist, on delayed response performance in chronic low dose MPTP-treated monkeys

1 reference

12 December 2020

"Full" dopamine D1 agonists in human caudate: biochemical properties and therapeutic implications

1 reference

12 December 2020

Identifiers

DOI

10.1038/NPP.2014.192

2 references

27 March 2017

Dimensions Publication ID

1010690146

0 references

1 reference

1 reference

PubMed publication ID

25074637

1 reference